



Gattefossé accelerates production ramp-up at its Lufkin facility with eight validated ingredients

PRESS RELEASE - Lyon, France – July, 8, 2026

Gattefossé, a leading provider of specialty ingredients and formulation solutions for the pharmaceutical and personal care industries, announces the successful validation of eight strategic ingredients at its Lufkin, Texas facility. Three pharmaceutical excipients and five cosmetic ingredients have now achieved manufacturing equivalency, marking a major milestone in the company's strategy to expand regional manufacturing while ensuring consistent quality and reliable supply worldwide.

A new manufacturing milestone for the Lufkin facility

The validation of three pharmaceutical excipients and five cosmetic ingredients reflects the rapid ramp-up of Gattefossé's Texas manufacturing facility since its inauguration and reinforces the company's manufacturing footprint in North America. Building on the **EXCiPACT® certification (GMP)** for pharmaceutical products and **EFfCI certification** for personal care products, the Lufkin site now manufactures these ingredients according to the same quality, analytical and regulatory standards applied across Gattefossé's global production network. Each validation is supported by a **complete technical equivalence file**, including analytical validation, stability data, and regulatory documentation to ensure seamless integration into customers' development and commercialization programs.

"The validation of our first ingredients at our Lufkin facility is a major achievement for our portfolio. Together, these eight excipients provide formulators with reliable solutions to address today's formulation challenges. By localizing the production of critical lipid-based excipients, we are directly answering our partners' need for supply chain resilience and dependable domestic sourcing in an increasingly unpredictable global market."

Ben Blinder, Chief Operating Officer at Gattefossé USA.



Three pharmaceutical excipients now manufactured in Texas

The pharmaceutical portfolio validated at Lufkin includes three flagship lipid excipients that support a wide range of drug delivery technologies.

- [Peceol™](#) is a lipid vehicle used as a solubilizer for lipophilic active pharmaceutical ingredients in oral and topical formulations.
- [Compritol® 888](#) is a lipid excipient widely recognized for modified-release drug delivery and lipid matrix technologies.
- [Geleol™ Mono and Diglycerides NF](#) is a multifunctional lipid excipient used as a lipidic vehicle and modified-release agent in oral, topical and semi-solid dosage forms.

Five cosmetic ingredients reinforce regional supply

Lufkin has also validated five strategic ingredients from Gattefossé's personal care portfolio.

[Emulium® Mellifera MB](#) is a natural oil-in-water emulsifier that adapts to different skin types and environmental conditions while delivering outstanding sensory properties.

[Compritol® 888 CG MB](#) is a multifunctional texturizing agent used as a consistency enhancer, oil-phase thickener and stabilizer in skincare, make-up and sun care formulations.

[Emulium® Delta MB](#) is an oil-in-water emulsifier offering high formulation flexibility together with a soft, velvety feel.

[Plurol® Diisostearique CG](#) is a water-in-oil emulsifier particularly suited to make-up and sun care formulations thanks to its minimalist composition and formulation versatility.

LAS MB is a versatile, non-ionic surfactant suitable for skin and hair care formulations, including creams, lotions, wipes and microemulsion systems.

Strengthening Gattefossé's global manufacturing network

Strategically located to better serve customers across the Americas, the Lufkin facility **reinforces Gattefossé's worldwide manufacturing network** by increasing production capacity, enhancing supply chain resilience, and ensuring greater business continuity.



By establishing large-scale oleochemical manufacturing in the United States, Gattefossé is expanding its ability to deliver high-quality lipid-based specialty ingredients while helping customers navigate supply chain challenges and an evolving geopolitical environment. This investment further reinforces the Group's position as a leading global supplier to both the pharmaceutical and personal care industries.

The Lufkin site is supported by Gattefossé's global network of Technical Centers of Excellence, located in the United States (Paramus, New Jersey), France, India, and China. These centers **combine local technical support with the Group's expertise in lipid chemistry** to accelerate formulation development and address regional market needs.



Together, this integrated manufacturing and technical network enables Gattefossé to deliver innovative solutions, reliable supply, and scientific excellence to customers wherever they operate.

Media Relations: Claudine Blondet – cblondet@gattefosse.com – tel: +33472229800 – www.gattefosse.com

About Gattefossé

The Gattefossé Group is a community of employees, animated by the same drivers: the performance of its products and the personalized support of its customers.

Gattefossé develops, manufactures and sells **pharmaceutical excipients and cosmetic ingredients of natural origin** for the beauty and health industries worldwide, through its 12 affiliated companies and network of global agents and distributors in 90 countries.

Specialist in **lipid chemistry and plant chemistry**, Gattefossé offers recognized expertise in formulation using its **4 Technical Centers of Excellence** in France, China, India and the United States.

Environmental and social issues have always been part of the culture of this **French and independent family business**, founded in Lyon in 1880. Today, Gattefossé relies on a purposeful **CSR approach**, Gatt'Up&Act, to build its innovation and development strategy.



People make our name